Total population | N=53 |
Clinical features | |
Age, median (IQR), years | 70 (66–76) |
Sex, male n (%) | 39 (74) |
BMI, median (IQR) | 25 (21–27) |
AF history,* n (%) | 6 (10) |
Hypertension, n (%) | 19 (36) |
Diabetes mellitus, n (%) | 6 (11) |
Coronary artery disease, n (%) | 2 (4) |
Valvular heart disease, n (%) | 0 (0) |
Heart failure history, n (%) | 2 (4) |
Pacemaker, n (%) | 1 (2) |
Smoking, n (%) | 14 (26) |
Obstructive sleep apnoea, n (%) | 0 (0) |
Thyroid disease, n (%) | 1 (2) |
Stroke history, n (%) | 2 (4) |
Major bleeding history, n (%) | 1 (2) |
CHADS2-VA2SC score, median (IQR) | 2 (1–3) |
HAS-BLED score, median (IQR) | 1 (1–2) |
Antithrombotic therapy | |
Antiplatelet therapy, n (%) | 7 (13) |
Anticoagulant therapy n (%) | 4 (8) |
Malignancy | |
CLL, n (%) | 38 (72) |
Waldenström disease, n (%) | 8 (15) |
Mantle lymphoma, n (%) | 4 (8) |
Marginal zone lymphoma, n (%) | 1 (2) |
Diffuse large B-cell lymphoma, n (%) | 2 (4) |
Prior oncological treatment, n (%) | 51 (96) |
Echocardiography | |
LAVI, median (IQR), mL/m2 | 32 (28–40) |
LVEF, median (IQR), % | 61 (57–66) |
Global longitudinal strain† (%) | 19 (−21–−17) |
*First diagnosed AF, n=1; paroxysmal AF, n=4; long-standing persistent AF, n=1.
†Values for n=47 patients.
AF, atrial fibrillation;BMI, body mass index;CLL, chronic lymphocytic leukaemia;LVAI, left atrial volume index;LVEF, left ventricular ejection fraction.